(Reuters) - AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and ...
Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its oncology, ...
A third shot of the Oxford/AstraZeneca vaccine could be an effective booster jab without the need for tweaks, new research suggests. An Oxford University study found that giving people a third dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results